.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01D_OtherBetaLactamAntibacterials.J01DD58_CefiximeAndBetaLactamaseInhibito.CefiximeAndBetaLactamaseInhibito

Information

Cefixime is a third-generation oral cephalosporin antibiotic used to treat a range of bacterial infections, including respiratory tract, urinary tract, and sexually transmitted infections. Beta-lactamase inhibitors are agents that extend the spectrum of beta-lactam antibiotics by inhibiting beta-lactamase enzymes produced by bacteria, which would otherwise degrade the antibiotic. The fixed-dose combination of cefixime and a beta-lactamase inhibitor is intended to overcome resistance in beta-lactamase-producing organisms. As of now, such fixed-dose combinations are used in some countries but are not broadly approved in the US/Europe.

Pharmacokinetics

Estimated pharmacokinetic parameters for the combination product (cefixime and beta-lactamase inhibitor) in healthy adults, based on known PK of cefixime and class properties of oral beta-lactamase inhibitors.

References

1. Birgy, A, et al., & Bonacorsi, S (2021). Clavulanate combinations with mecillinam, cefixime or cefpodoxime against ESBL-producing Enterobacterales frequently associated with blaOXA-1 in a paediatric population with febrile urinary tract infections. The Journal of antimicrobial chemotherapy 76(11) 2839–2846. DOI:10.1093/jac/dkab289 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34453533

2. Koeth, LM, et al., & Saunders, KA (2004). Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 8(6) 362–373. DOI:10.1016/j.ijid.2004.02.005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15494258

Revisions

• 06/2025 initial generated model